May 26, 2020
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
May 19, 2020
Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD Monitoring
Sep 24, 2019
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
Jul 17, 2019
Hematogenix Announces the Global Availability of BCMA Flow Cytometry and IHC Assays
Jun 16, 2019
Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
Jan 22, 2019
European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Jan 07, 2019
In Promise of True Liquid Biopsy for Cancer, Chip Company BioFluidica® Awarded $1.7 Million by National Cancer Institute/National Institutes of Health for Clinical Trial in Children with Acute Lymphoblastic Leukemia
Oct 24, 2018
Trovagene Announces New Patent Claim Allowances Affirming Broad Patent Portfolio Coverage of NPM1 Mutations by U.S. Patent and Trademark Office
Jun 15, 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
May 16, 2018
In Promise of True Liquid Biopsy for Cancer, BioFluidica® Launches Human Trial for Rapid Detection of Minimal Residual Disease in Acute Myeloid Leukemia from Peripheral Blood Using high through-put automation and programmable Microfluidic Chips
Apr 10, 2018
Hematogenix Laboratory Services Launches Minimal Residual Disease (MRD) Evaluation for Chronic Lymphocytic Leukemia (CLL) Using the Standardized ERIC Method
Mar 29, 2018
FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
Mar 29, 2018
FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse
Feb 14, 2018
Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)
Sep 26, 2017
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration